The main barriers are bioavailability (how much drug actually enters the bloodstream), stability (peptides degrade when exposed to skin temperature and enzymes), and patient compliance (patches still require weekly changes and site monitoring)
Medicare Part D still does not cover weight-loss drugs as a standard benefit, though the Treat and Reduce Obesity Act has been pushing to change that
Examples include: high blood pressure, blood vessel disease, thyroid cancer, high blood sugar, kidney disease, acute kidney injury, cardiovascular disease, fatty liver disease, and other serious health problems Pregnancy and Breastfeeding: Caution is advised due to unclear safety during these periods
2018;1864(9 Pt B):281421
The endogenous inhibitor of growth hormone release